Skip to main content

Table 3 Baseline demographic and clinical variables and domain scores associated with treatment duration

From: Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment

Variables

Univariatea

Multivariatea

HR (95 % CI)

P value

HR (95 % CI)

P value

Baseline characteristics

Age <70 y (vs. ≥70 y)

0.749 (0.343–1.429)

0.380

  

Sex, male (vs. female)

0.634 (0.307–1.308)

0.217

  

HCV infection (vs. other etiology)

1.796 (0.964–3.348)

0.065

  

Child Pugh = 5 (vs. ≥6)

0.511 (0.271–0.962)

0.038

  

TMN stage III (vs. IV)

0.672 (0.357–1.264)

0.218

  

Vascular invasion – (vs. +)

0.355 (0.178–0.710)

0.003

0.382 (0.186–0.786)

0.009

Tumor size <50 mm (vs. ≥50 mm)

0.777 (0.412–1.466)

0.432

  

Previous curative therapy: Yes (vs. No)

0.433 (0.226–0.829)

0.012

  

AFP <100 (vs. ≥100)

1.048 (0.561–1.961)

0.954

  

DCP <1000 (vs. ≥1000)

0.473 (0.509–0.912)

0.025

0.509 (0.261–0.993)

0.048

Initial dose of sorafenib 800 mg (vs. <800 mg)

0.744 (0.388–1.426)

0.373

  

HRQOL domain scores ≥40:b

Physical functioning

0.956 (0.509–1.799)

0.889

  

Role physical

0.771 (0.416–1.429)

0.408

  

Bodily pain

1.582 (0.728–3.436)

0.247

  

General health

1.034 (0.516–2.070)

0.926

  

Vitality

1.534 (0.631–3.731)

0.346

  

Social functioning

0.395 (0.185–0.840)

0.016

0.452 (0.206–0.995)

0.049

Role emotional

0.898 (0.455–1.770)

0.755

  

Mental health

0.833 (0.379–1.828)

0.649

  
  1. HR hazard ratio, CI confidence interval, HCV hepatitis C virus, TNM tumor-node-metastasis, AFP alpha fetoprotein, DCP des-gamma-carboxy prothrombin; HRQOL, health related quality of life
  2. aCox proportional hazards regression analysis
  3. bAll domain scores are relative to scores <40
  4. All variables with P values <0.05 in the univariate analysis were included in the multivariate analysis